Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: A systematic review

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Valenti, Raffaella ^a   Pantoni, Leonardo ^b   Markus, Hugh S ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Cholesterol; Dementia; Diabetes mellitus; Hypertension; Progression; Smoking; Statin; Treatment; Vascular risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COGNITION; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTEMATIC REVIEW; COMPLICATION; OBSERVATIONAL STUDY; RISK FACTOR; STROKE;

ALZHEIMER DISEASE; HUMANS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 84920861405     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-014-0160-z     Document Type: Article

References (55)

1. Barreto Pde S: Alzheimer's disease: learning from the past, looking to the future. Am J Alzheimers Dis Other Demen 2013, 28:304-305.
2. Reitz C, Mayeux R: Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014, 88:640-651.
3. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013, 136:2697-2706.
4. Breteler MM: Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000, 21:153-160.
5. Connolly A, Campbell S, Gaehl E, Iliffe S, Drake R, Morris J, Martin H, Purandare N: Under-provision of medical care for vascular diseases for people with dementia in primary care: a cross-sectional review. Br J Gen Pract 2013, 63:e88-e96.
6. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ: Midlife blood pressure and dementia: The Honolulu-Asia Aging study. Neurobiol Aging 2000, 21:49-55.
7. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942.
8. Diomedi M, Misaggi G: Vascular contribution to Alzheimer disease: predictors of rapid progression. CNS Neurol Disord Drug Targets 2013, 12:532-537.
9. Richard E, Kuiper R, Dijkgraaf MG, van Gool WA, Evaluation of Vascular care in Alzheimer's disease: Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc 2009, 57:797-805.
10. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H: Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004, 63:1324-1325.
11. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T: Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatrics Gerontol Int 2012, 12:207-214.
12. Balfour JA, Plosker GL: Rosiglitazone. Drugs 1999, 57:921-930.
13. Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A: Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007, 11:45-51.
14. Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
15. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK: Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR-. Mol Cell 2007, 25:57-70.
16. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E: Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor-agonist. J Neurosci 2008, 28:9287-9296.
17. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR: Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199:265-273.
18. Toledo EM, Inestrosa NC: Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1 mouse model of Alzheimer's disease. Mol Psychiatry 2010, 15:272-285.
19. Craft S: Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007, 4:147-152.
20. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005, 13:950-958.
21. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T: Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009, 57:177-179.
22. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T: Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011, 32:1626-1633.
23. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer's Disease Study Group: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006, 6:246-254.
24. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S: Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010, 30:131-146.
25. Austen B, Frears E, Davies H: Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging 2000, 21:254.
26. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998, 95:6460-6464.
27. Sparks DL, Hunsaker JC 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR: Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990, 11:601-607.
28. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000, 7:321-331.
29. Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ: Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Ann N Y Acad Sci 2000, 903:335-344.
30. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P: Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2005, 2:527-539.
31. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB: Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002, 52:346-350.
32. Winblad B, Jelic V, Kershaw P, Amatniek J: Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging 2007, 24:57-61.
33. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A, LEADe Investigators: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964.
34. Deschaintre Y, Richard F, Leys D, Pasquier F: Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009, 73:674-680.
35. Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R, Lyketsos CG: Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 2008, 16:883-892.
36. Razay G, Williams J, King E, Smith AD, Wilcock G: Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study. Dement Geriatr Cogn Disord 2009, 28:70-74.
37. Duron E, Rigaud AS, Dubail D, Mehrabian S, Latour F, Seux ML, Hanon O: Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens 2009, 22:1020-1024.
38. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004, 18:208-213.
39. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 12:340:b5465.
40. Hajjar IM, Keown M, Lewis P, Almor A: Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen 2008, 23:77-83.
41. Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, Rolland Y, Vellas B: Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort. J Am Geriatr Soc 2013, 61:1482-1488.
42. Ellul J, Archer N, Foy CM, Poppe M, Boothby H, Nicholas H, Brown RG, Lovestone S: The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2007, 78:233-239.
43. Kehoe PG, Davies NM, Martin RM, Ben-Shlomo Y: Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 2013, 33:999-1008.
44. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, Spanò A, Gallo D, Mungari P, Consoli D, Bosco D: Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010, 288:112-116.
45. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, Pasquier F: Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005, 76:1624-1629.
46. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. [http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm]
47. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM: Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
48. Padala KP, Padala PR, Potter JF: Statins: a case for drug withdrawal in patients with dementia. J Am Geriatr Soc 2010, 58:1214-1216.
49. Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB: Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
50. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB: Randomized trial of the effects of simvastatin on cognitive function in in hypercholesterolemic adults. Am J Med 2004, 117:823-829.
51. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, Unverzagt F, Hui S, Hendrie HC: Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc 2006, 54:104-109.
52. Dhikav V, Singh P, Anand KS: Medication adherence survey of drugs useful in prevention of dementia of Alzheimer's type among Indian patients. Int Psychogeriatr 2013, 25:1409-1413.
53. Blais L, Kettani FZ, Perreault S, Leroux JC, Forget A, Kergoat MJ: Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriatr Soc 2009, 57:366-368.
54. Roe CM, Anderson MJ, Spivack B: How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002, 16:49-51.
55. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-Dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.